Evidence map›Paper›PMID 30352669›Full record

ArticleJournal of substance abuse treatment2018

Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Andrea K Finlay, Ingrid A Binswanger, Christine Timko, David Smelson, Matthew A Stimmel, Mengfei Yu, Tom Bowe, Alex H S Harris

Abstract readMulticenter Study
In one paragraph

Article in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Andrea K FinlayCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA; National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Andrea.Finlay@va.gov.
Ingrid A BinswangerInstitute for Health Research, Kaiser Permanente Colorado, P.O. Box 378066, Denver, CO 80237-8066, USA; Division of General Internal Medicine, University of Colorado School of Medicine 12631 E. 17(th) Ave., Academic Office One, Campus Box B180, Aurora, CO 80045, USA. Electronic address: Ingrid.A.Binswanger@kp.org.
Christine TimkoCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA; Department of Psychiatry and Behavioral Medicine, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA. Electronic address: ctimko@stanford.edu.
David SmelsonCenter for Organization and Implementation Science, Edith Nourse Rogers VA Medical Center, 200 Springs, Bedford, MA 01730, USA. Electronic address: David.Smelson@va.gov.
Matthew A StimmelVeterans Justice Outreach Program, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Matthew.Stimmel@va.gov.
Mengfei YuCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Mengfei.Yu@va.gov.
Tom BoweCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA. Electronic address: Thomas.Bowe@va.gov.
Alex H S HarrisCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA; Department of Surgery, Stanford University School of Medicine, Alway Building, Room M121, 300 Pasteur Drive, Stanford, CA 94305-2200, USA. Electronic address: Alexander.Harris2@va.gov.
VA Palo Alto Health Care System · USStanford University · USEdith Nourse Rogers Memorial Veterans Hospital · USKaiser Permanente · US

Funding

Improving Access to Pharmacotherapy for Opioid Use Disorder Among Justice Involved VeteransR21DA041489 · NIDA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI FINLAY, ANDREA K · 2017 to 2018
$473k
Justice-Involved Veterans: Mental Health and Substance Use Care of Young AdultsIK2HX001513 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI FINLAY, ANDREA K · 2019 to 2020
–
HSRD VA CDA 13-279HSRD VA IK2 HX001513HSRD VA RCS 00-001HSRD VA RCS 14-232NIDA NIH HHS R21 DA041489
6 · The paper itself

Abstract

backgroundThe U.S. is facing an opioid epidemic, but despite mandates for pharmacotherapy for opioid use disorder to be available at Veterans Health Administration (VHA) facilities, the majority of veterans with opioid use disorder do not receive these medications. In implementation research, facilities are often targeted for qualitative inquiry or quality improvement efforts based on quality measure performance during a one-year period. However, sites that experience quality performance changes from one year to the next may be highly informative because mechanisms that impact facility change may be more discoverable. The current study examined changes in receipt of pharmacotherapy for opioid use disorder in a national healthcare system to determine the extent to which sites fluctuated in performance over a two-year period and illustrate how changes in quality measures over time may be useful for implementation research and healthcare surveillance of quality measures.

methodsUsing national VHA data from Fiscal Years (FY) 2016 and 2017, we calculated quality measure performance as the number of patients who received pharmacotherapy for opioid use disorder (i.e., methadone, buprenorphine, and naltrexone) divided by the number of patients with a current non-remitted opioid use disorder diagnosis for each FY at each facility (n = 129) and examined change from FY16 to FY17.

resultsThe mean rate of receipt of pharmacotherapy for opioid use disorder was 38% (facility range = 3% to 74%) in FY16 and 41% (facility range = 2% to 76%) in FY17. The average facility-level change in performance was 3% and ranged from -19% to 26%. There were 32 facilities that decreased in provision of pharmacotherapy, 12 facilities with no change, and 85 facilities that increased.

conclusionsFor facilities with average or high performance, it was difficult to maintain their performance over time. Identifying and learning from facilities with recent fluctuations may be more informative to guide the design of future quality improvement efforts than studying facilities with stable high or low performance.

Indexed as

Quality Indicators, Health CareBuprenorphineHospitals, VeteransHumansImplementation ScienceMethadoneNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersQuality ImprovementUnited StatesUnited States Department of Veterans AffairsVeteransBuprenorphineMethadoneNaltrexoneBuprenorphineImplementation scienceMethadoneOpioid-related disordersPharmacotherapyUnited States Department of Veterans Affairs

Identifiers

PMID30352669
PMCPMC6209329
OpenAlexW2895757271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.